Ajanta Pharma Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2025, declared Interim Dividend of Rs. 28 per equity share.
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajanta Pharma's board, meeting on November 3, 2025, declared a 1st interim dividend of Rs. 28 per equity share on a face value of Rs. 2, totaling a payout of about Rs. 349.82 crore. The record date is fixed as November 10, 2025, with payment on or after November 20, 2025. For Q2 FY26, consolidated revenue grew 14% year-on-year to Rs. 1,354 crore, while profit after tax rose 20% to Rs. 260 crore; EBITDA was Rs. 328 crore (up 5%), though it included a Rs. 41 crore mark-to-market forex loss. For H1 FY26, revenue rose 14% to Rs. 2,656 crore and PAT climbed 12% to Rs. 516 crore, with healthy ROCE of 30% and RONW of 25%. The US generics segment led growth, jumping 48% in Q2 and 42% in H1. The company also flagged that Income Tax Authorities conducted search operations at certain premises in August 2025, with no formal communication received yet and no adjustments made.
Healthy double-digit earnings growth and a sizable dividend payout signal strong cash generation and shareholder-friendly policy. However, the unresolved Income Tax search in August 2025 is a pending overhang that investors should monitor for any further developments.